Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Apr
9
2019
Ninth Circuit Sends Brain-Booster Claim Case Back to District Court Proskauer Rose LLP
Apr
9
2019
FDA Announces Citizen Petition to Grant Fiber Status to IMO Keller and Heckman LLP
Apr
9
2019
FDA issues statement on future of CBD and Cannabis-derived products, recent enforcement actions Godfrey & Kahn S.C.
Apr
9
2019
FDA Releases Warning Letters to CBD and Hemp Oil Companies McDermott Will & Emery
Apr
9
2019
Fashion & Food Industry Update: More Companies Adopting Blockchain Solutions K&L Gates
Apr
8
2019
CBD Update: FDA Issues Statement, Calls Public Hearing, and Announces Warning Letters on Products Containing Cannabis and its Components Robinson & Cole LLP
Apr
8
2019
Cannabis Finance - SAFE in the STATES and Maybe Beyond? Cadwalader, Wickersham & Taft LLP
Apr
8
2019
Bashful Bladders Bring Problems for Employers
Apr
8
2019
Congress Keeping its Focus on Drug Costs Mintz
Apr
8
2019
Latest FDA Data Show Foodborne Pathogens in Fresh Herbs, Guacamole, and Processed Avocado; The Source of a New Multistate E. coli O103 Outbreak Remains a Mystery Keller and Heckman LLP
Apr
5
2019
ECHA PEG Reviewing Draft Appendix for Nanoforms Applicable to the Guidance on Registration and Substance Identification Bergeson & Campbell, P.C.
Apr
5
2019
Ohio Workers’ Compensation System Does Its Part to Mitigate the Opioid Epidemic’s Impact on the State’s Workforce (US) Squire Patton Boggs (US) LLP
Apr
5
2019
New Hazardous Waste Pharmaceutical Rule Imposes New Obligations on Health Care Providers Van Ness Feldman LLP
Apr
5
2019
McDermottPlus Check-Up: April 5, 2019 McDermott Will & Emery
Apr
5
2019
FDA Issues Guidance on Hops and Wine Grapes McDermott Will & Emery
Apr
5
2019
FDA Highlights Advances In Animal Biotechnology Product Development Bergeson & Campbell, P.C.
Apr
5
2019
Oklahoma’s Unity Bill Allows Employers to Prohibit Medical Marijuana Use by Employees in Safety-Sensitive Positions Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Apr
5
2019
USDA APHIS Requests Public Comments On dEA And dPPRA Draft Documents Bergeson & Campbell, P.C.
Apr
5
2019
FDA Releases Heavy Metal Test Results in Kratom Keller and Heckman LLP
Apr
4
2019
Federal Circuit Addresses Obviousness of Polymorphs in Grunenthal GmbH v. Alkem Labs. Ltd., No. 2017-1153 (Fed. Cir. Mar. 28, 2019) Polsinelli PC
Apr
4
2019
Medical Marijuana Delivery App Agrees to Settle TCPA Case for $1.75M Robinson & Cole LLP
Apr
4
2019
Cleveland Clinic II – Why Can’t a Diagnostic Conclusion be a Practical Application of a Natural Law?
Apr
4
2019
Washington Court of Appeals Upholds Multi-Million Dollar Fine for 5-Hour Energy Advertising Claims McDermott Will & Emery
Apr
4
2019
FDA Encourages Participation in Voluntary Plant Biotechnology Consultation Program and Revises Guidance on Voluntary Labeling of Foods Derived Plant Biotechnology Keller and Heckman LLP
Apr
4
2019
FDA Updates Guidance for CBD Products amid a New Round of Warning Letters and Announcement of Date for Public Hearing Wilson Elser Moskowitz Edelman & Dicker LLP
Apr
3
2019
340B Drug Ceiling Prices Now Available Dinsmore & Shohl LLP
Apr
3
2019
CMS’s New Part D Policies Address the Opioid Epidemic Mintz
Apr
3
2019
FDA Commissioner Gottlieb Says Agency Will Not Tolerate Deceptive Marketing of CBD Products; Issues Warning Letters Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins